Topic Hub
10 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 10 of 10 clinical reviews.
A clinically detailed review of how AndroGel (testosterone gel) may behave differently in Black and African ancestry patients, covering pharmacogenomics, cardiovascular risk, hypertension, CKD, G6PD status, and ethnicity-stratified dosing guidance.
Read clinical reviewEvidence-based guide to adjusting AndroGel (testosterone gel) dosing in South Asian men, covering pharmacogenomic factors, cardiovascular risk thresholds, and monitoring protocols specific to this population.
Read clinical reviewA clinical deep-dive into AndroGel (testosterone gel) dose adjustments for Black and African ancestry men, covering pharmacogenomics, ethnicity-stratified trial data, cardiovascular risk, and practical dosing guidance.
Read clinical reviewEast Asian patients on AndroGel (testosterone gel 1% or 1.62%) may need dose modifications due to CYP enzyme polymorphisms, lower average BMI, and SHBG differences. This clinician-reviewed guide covers the evidence, dosing frameworks, and monitoring protocols.
Read clinical reviewA clinician-reviewed guide to AndroGel pharmacogenomics, dosing thresholds, and safety considerations specific to East Asian patients, with cited trial data and pharmacogenomic references.
Read clinical reviewA clinical deep-dive into why AndroGel (testosterone 1% and 1.62% gel) may produce smaller testosterone rises in Hispanic and Latino men, covering CYP enzyme variants, SHBG differences, insulin resistance, and ethnicity-stratified trial data.
Read clinical reviewA clinical deep-dive into AndroGel (testosterone gel) dosing for Hispanic and Latino patients, covering pharmacogenomics, CYP enzyme variants, insulin resistance, and ethnicity-stratified trial data.
Read clinical reviewA clinical review of AndroGel (testosterone gel 1% and 1.62%) efficacy differences in Black and African ancestry patients, covering pharmacogenomics, CYP enzyme variation, SHBG differences, dosing considerations, and ethnicity-stratified trial data.
Read clinical reviewHow South Asian genetics, cardiovascular risk thresholds, and metabolic patterns affect AndroGel (testosterone gel) safety, dosing, and monitoring. Evidence-based guidance for clinicians and patients.
Read clinical reviewSouth Asian men prescribed AndroGel (testosterone 1.62% gel) may achieve lower serum testosterone levels and face distinct cardiovascular risks compared with other populations. This guide covers pharmacogenomic differences, dosing considerations, and what current evidence says about ethnicity-specific gaps.
Read clinical review